Dr Reddy’s Q1FY26 earnings are expected to show steady revenue growth and resilient domestic demand, with mixed profit estimates ranging from a 2% decline to 15% growth. US performance may be tempered by lower Revlimid sales, while domestic strength continues to support margins.
